AR029152A1 - Benzo[de]isoquinolin-1,3-dionas sustituidas, un procedimiento para prepararlas, las composiciones farmaceuticas que las contienen, un metodo para controlar los trastornos tromboticos que las emplea, un metodo para inducir un efecto antiadhesivo sobre las plaquetas sanguineas empleando las benzo[de]i - Google Patents

Benzo[de]isoquinolin-1,3-dionas sustituidas, un procedimiento para prepararlas, las composiciones farmaceuticas que las contienen, un metodo para controlar los trastornos tromboticos que las emplea, un metodo para inducir un efecto antiadhesivo sobre las plaquetas sanguineas empleando las benzo[de]i

Info

Publication number
AR029152A1
AR029152A1 ARP990105972A ARP990105972A AR029152A1 AR 029152 A1 AR029152 A1 AR 029152A1 AR P990105972 A ARP990105972 A AR P990105972A AR P990105972 A ARP990105972 A AR P990105972A AR 029152 A1 AR029152 A1 AR 029152A1
Authority
AR
Argentina
Prior art keywords
formula
group
nha
conh
het
Prior art date
Application number
ARP990105972A
Other languages
English (en)
Inventor
Mederski Werner Dr
Devant Ralf Dr
Bernotat-Danielowki Sabine Dr
Melzer Guido Dr
Raddatz Peter Dr
Zhengdong Wu
Daljit Dhanoa
Richard Soll
James Rinker
Todd Graybill
Barnickel Gernard Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR029152A1 publication Critical patent/AR029152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Benzo[de]isoquinolin-1,3-dionas sustituidas, de formula (1) en donde R representa H, A o CH2-Ph, R1 representa ûHet, -N-[(CH2)s-OH]2, -N-[(CH2)s-OA]2, -NA-(CH2)s-Ar, -NA-(CH2)m-R5, -Y-(CH2)m-R5, -Y-(CH2)2-NHA, -Y-(CH2)2-NH-(CH2)s-OH, -Y-(CH2)2-NA2, -Y-(CH2)m-OH, -Y-(CH2)n-(CHR4)-R3, -Y-(CH2)n-R4, R4, -Y-(CH2)n-Het-(CH2)o -R6, -Y-(CH2)n-Ar'-(CH2)o-R6, -Het û(CH2)n-Ar, Het-Het, -Y-(CH2)s-Ar' û(CH2)o -R11, -Y-[X-O]t-[X1-O]u-X2-R5 o-Y-(CH2)n-NA-(CH2)o-R5, R2 representa H, OH, OA, COOH, COOA, CH(Ph)-Ph, Ar, Het1, R5, R7 o R8, R3 representa CH3, R4 representa ûCH=CH2, -Ar, COOA, COOH, de formula (2) o (3), R5 representa NH2, NHA, NA2, NHAr, -NH-(CH2)n-OH o ûNH-(CH2)n-OA, R6 representa H o R5, R7 representa ûAr'-(CH2)n-R8 o ûAr'-(CH2)n-R5, R8 representa CONH2, CONHA, CONA2, CONH-(CH2)o -Ar, CONH-(CH2)o-Het, CONH-(CH2)o-R5, CONH-(CH2)o -CH(Ar1)-Ar2, CONH-(CH2)o -(CH(A)-Ph, CONH-(CH2)o-Ar' û NH-CO-Ar, CONH-Ar' ûHet o CHA-CONH2, R11 representa ûNH-(C=NH)-NH2, NH-(C=NH)-NHA, -NH-(C=NH)-NA2, -NA-(C=NH)-NH2, NA-(C=NH)-NHA o û NA-(C=NH)-NA2, Ar' representa fenileno, cicloalquileno o bifenileno, el cual puede estar no sustituido o mono o disustituido con A, OH, OA, Hal, CN, NH2, NHA, NA2, NO2, CF3, CO-A, SO2NH2, SO2NAH, SO2NA2, Ar representa fenilo, cicloalquilo, naftilo, ciclohex-1-enilo, bifenilo, biciclohexilo, 4-ciclohexil-fenilo, benzo[1,3]dioxol-5-ilo o indanilo, el cual se encuentra no sustituido o mono, di o trisustituido con A, OH, OA, O-Ph, O-CH2-Ph, O-Ph-CH3, O(cicloalquilo), Hal, CN, NH2, NHA, NA2, NH-C(O)A, (CH2)n-NH2, (CH2)n-NHA, (CH2)n-NA2, NO2, CF3, C(O)A, SO2-Ph, SO2NH2, SO2NAH, SO2NA2 o SO2NA-Ph, Ar1 y Ar2 representan independientemente fenilo, Het representa un resto heterocíclico mono o bi-cíclico, saturado o parcialmente o totalmente insaturado, con 5 a 10 miembros en el anillo, que puede contener 1 o 2 átomos de N y/o 1 o 2 átomos de S u O y que puede estar mono o disustituido con CN, Hal, OH, OA, CF3, A, NO2, CO, CO-A o R5, Het1 representa un resto heterocíclico o mono o bicíclico insaturado con 5 a 10 miembros en el anillo, que puede contener 1 o 2 átomos de N y/o 1 o 2 átomos de S u O y/o puede estar mono o disustituido con Hal, OH, OA, A representa alquilo de C1-6 de cadena recta o ramificada, Hal representa F, Cl, Br o I, X, X1, X2 representa independientemente alquileno de 1 a 12 átomos de C, Y representa O, S o NH, i es 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 o 12, m es 3, 4, 5, 6, 7, 8, 9, 10, 11 o 12, n, o son independientemente 0, 1, 2, 3 o 4, s es 1, 2, 3, o 4, t es 0, 1 o 2, u es 1 o 2, considerando que cuando R2 representa Ar o H, R1 no puede representar la formula (4) y sus sales y solvatos aceptables desde el punto de vista farmacéutico. Un procedimiento para preparar los compuestos de formula (i) en el cual (a) se libera un compuesto de formula (1) de uno de sus derivados funcionales por tratamiento con un agente de solvolisis o hidrogenolisis o (b) se hace reaccionar un compuesto de formula (5) en donde R9 representa Cl, Br, NO2 o R1 y R1 tiene el significado indicado en la reivindicacion 1, con un compuesto de formula: H2N-(CHR)i-R2 en donde R, R2 e i tienen el significado indicado en la reivindicacion 1, y, si es necesario, se transforma el resto R9 en un resto R1 o (c) se hace reaccionar un compuesto de la formula (6) en donde R9 representa Cl, Br, NO2, o R1 y R1 tiene el significado indicado en la reivindicacion (1), con un compuesto de formula: L-(CHR)i-R2 en donde L representa Cl, Br o I, OH o un grupo de OH reactivo y esterificado, y R, R2 e i tienen el significado indicado en la reivindicacion 1, y, si es necesario, se transforma el resto R9 en un resto R1, o (d) se transforma un resto R y/o R2 y/o R9 en otro resto R y/o R2 y/o R9 ya sea por ejemplo, transformando un grupo de amino en un grupo de guanidino por reaccion con un agente de amidinacion, haciendo reaccionar un bromuro o yoduro de arilo para obtener los productos de acoplamiento correspondientes por medio de un acoplamiento de Suzuki con ácidos boricos, reduciendo un grupo nitro, un grupo sulfonilo o un grupo sulfoxilo, esterificando un grupo OH o escindiendo el éter de un grupo OA, alquilando un grupo amino primario o secundario, hidrolizando parcial o totalmente con un grupo CN escindiendo un grupo éster o esterificando un resto de ácido carboxílico, o llevando a cabo una sustitucion nucleofila o electrofila, y/o (e) se transforma una base o un ácido de formula (1) en una de sus sales o en uno de sus solvatos. Las composiciones farmacéuticas que contienen al menos una cantidad efectiva de un compuesto de formula (1) o de una de sus sales o uno de sus solvatos aceptables desde el punto de vista fisiologico, y que son efectivas como antagonistas de la glicoproteína IblX, en particular para el control de los trastornos tromboticos y las secuelas que derivan de ellos. Entre estas secuelas se incluye el infarto del miocardio, la arteriosclerosis, la angina de pecho, el síndrome coronario agudo, el trastorno circulatorio periférico, el ataque apoplético, el ataque isquémico transiente o la reoclusion o restenosis después de una angioplastia o una implantacion.
ARP990105972A 1998-11-25 1999-11-24 Benzo[de]isoquinolin-1,3-dionas sustituidas, un procedimiento para prepararlas, las composiciones farmaceuticas que las contienen, un metodo para controlar los trastornos tromboticos que las emplea, un metodo para inducir un efecto antiadhesivo sobre las plaquetas sanguineas empleando las benzo[de]i AR029152A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19940998A 1998-11-25 1998-11-25
US40099299A 1999-09-21 1999-09-21

Publications (1)

Publication Number Publication Date
AR029152A1 true AR029152A1 (es) 2003-06-18

Family

ID=26894739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105972A AR029152A1 (es) 1998-11-25 1999-11-24 Benzo[de]isoquinolin-1,3-dionas sustituidas, un procedimiento para prepararlas, las composiciones farmaceuticas que las contienen, un metodo para controlar los trastornos tromboticos que las emplea, un metodo para inducir un efecto antiadhesivo sobre las plaquetas sanguineas empleando las benzo[de]i

Country Status (15)

Country Link
EP (1) EP1133475A1 (es)
JP (1) JP2002530379A (es)
CN (1) CN1328549A (es)
AR (1) AR029152A1 (es)
AU (1) AU1504900A (es)
BR (1) BR9915611A (es)
CA (1) CA2351348A1 (es)
CZ (1) CZ20011792A3 (es)
HU (1) HUP0104469A3 (es)
ID (1) ID29425A (es)
MX (1) MXPA01005228A (es)
NO (1) NO20012543D0 (es)
PL (1) PL347766A1 (es)
SK (1) SK7012001A3 (es)
WO (1) WO2000031039A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104236D0 (en) 2001-02-21 2001-04-11 Clariant Int Ltd New dye compounds
GB0104240D0 (en) 2001-02-21 2001-04-11 Clariant Int Ltd Copolymer composition having pigment like properties
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
US8097725B2 (en) 2004-12-03 2012-01-17 Roche Diagnostics Operations, Inc. Luminescent indicator dye and optical sensor
WO2012115945A1 (en) * 2011-02-21 2012-08-30 The Board Of Regents Of The University Of Texas System Viral inhibitors
CN103848787A (zh) * 2012-12-06 2014-06-11 中国科学院大连化学物理研究所 一种荧光探针及其在可逆检测次氯酸中的应用
EP3348555B1 (en) 2013-03-15 2020-11-25 Alumend, LLC Compositions and methods of using the compositions for plaque softening
WO2014179567A2 (en) * 2013-05-01 2014-11-06 Academia Sinica Methods and compositions for treating beta-thalassemia and sickle cell disease
WO2018212355A1 (ja) * 2017-05-19 2018-11-22 株式会社同仁化学研究所 蛍光化合物及びそれを用いたオートファジー検出試薬
CN111253368B (zh) * 2018-11-30 2020-12-25 沈阳药科大学 一类稳定氮氧自由基修饰的萘酰亚胺类化合物及其应用
CN111777557B (zh) * 2020-07-28 2022-11-22 中国科学院上海有机化学研究所 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用
CN113087702B (zh) * 2021-03-29 2022-07-12 苏州大学 一种多功能过氯乙烯衍生物及其制备方法与应用
WO2023166531A1 (en) * 2022-03-04 2023-09-07 Jawaharlal Nehru Centre For Advanced Scientific Research Amyloid and associated pathology modulators and methods thereof
WO2024042539A1 (en) * 2022-08-22 2024-02-29 Jawaharlal Nehru Centre For Advanced Scientific Research Modulators of tau liquid-liquid phase separation and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
DE2360705A1 (de) * 1973-12-06 1975-06-26 Hoechst Ag Wasserunloesliche verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe
US4200752A (en) * 1978-02-16 1980-04-29 Bertelson Robert C 4-Disubstituted amino, N-substituted naphthalimide dyestuffs
JPS54160977A (en) * 1978-06-09 1979-12-20 Kawasaki Steel Corp Functioning speed changing method by means of operating lever
GB2183667B (en) * 1985-10-29 1989-11-22 Univ Brunel Preparation of amino-1;8-naphthalimides.
DE3614414A1 (de) * 1986-04-29 1987-11-05 Knoll Ag Neue benzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5308773A (en) * 1992-11-16 1994-05-03 Microbiomed Corp. Non-azo 1,8-naphthalimide dyes for the detection and quantitation of a paramagnetic metal cation in a non-aqueous medium
DE19505941A1 (de) * 1995-02-21 1996-08-22 Bayer Ag 1,8-Naphthalimid-Derivate, Verfahren zur Herstellung und ihre Verwendung als Zwischenprodukte
DK0930883T3 (da) * 1996-10-21 2006-05-22 Nps Allelix Corp Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte

Also Published As

Publication number Publication date
PL347766A1 (en) 2002-04-22
WO2000031039A1 (en) 2000-06-02
HUP0104469A2 (hu) 2002-04-29
CZ20011792A3 (cs) 2001-09-12
ID29425A (id) 2001-08-30
HUP0104469A3 (en) 2003-06-30
AU1504900A (en) 2000-06-13
NO20012543L (no) 2001-05-23
BR9915611A (pt) 2001-08-14
SK7012001A3 (en) 2001-11-06
EP1133475A1 (en) 2001-09-19
MXPA01005228A (es) 2002-06-21
CA2351348A1 (en) 2000-06-02
NO20012543D0 (no) 2001-05-23
JP2002530379A (ja) 2002-09-17
CN1328549A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
AR029152A1 (es) Benzo[de]isoquinolin-1,3-dionas sustituidas, un procedimiento para prepararlas, las composiciones farmaceuticas que las contienen, un metodo para controlar los trastornos tromboticos que las emplea, un metodo para inducir un efecto antiadhesivo sobre las plaquetas sanguineas empleando las benzo[de]i
AR005245A1 (es) Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
AR109033A2 (es) Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso
AR043938A1 (es) Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
DE60311995D1 (de) Neue purine derivate
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
IL166783A (en) 6 - [(pyridine-2-yl-methyl) -amino] - h9-purine-2-yl amino alcohol, process for preparation and medical preparations containing them
ATE177752T1 (de) Neue inhibitoren von faktor xa
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
DK0992501T3 (da) Pyridoncarboxylsyre derivater som antibakterielle midler
TR200100438T2 (tr) Hepatit C inhibitörü peptitler
AU2001281483A1 (en) Method of preparing alkylated salicylamides via a dicarboxylate intermediate
AR040257A1 (es) Profarmacos de aminoacidos excitadores
AR020688A1 (es) Derivados de la imidazo [4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones f
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR033879A1 (es) Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
BR9814055A (pt) Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto
AR022220A1 (es) Derivados de la imidazo[4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones fa
PE17798A1 (es) Derivados de aminoacidos excitadores
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
GT199900006A (es) Nuevos pentasacaridos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DE60002949D1 (de) Verfahren zur Herstellung des Neuraminidase-Inhibitoren ro-64-0796
AR022628A1 (es) Derivados de la beta-alanina, un procedimiento para su preparacion, las composiciones farmaceuticas que los contienen, el empleo de los mismos parapreparar un medicamento y como inhibidores de integrinas.
ATE253359T1 (de) Antithrombotische mittel
DK0599240T3 (da) Indol-7-carboxamidderivater som analgetika

Legal Events

Date Code Title Description
FA Abandonment or withdrawal